As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

PFS came in at 61.6% overall, at 62.9% in those with stable brain metastases, and at 59.6% in those with active brain ...

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...

Enhertu has shown 'unprecedented' trial results, giving hope to mums like Maggie Ngatai.

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

The data as well as the results in patients without brain metastases further build confidence in the clinical profile of ENHERTU for the second-line treatment of HER2-positive metastatic breast cancer ...

AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and ...

Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu ...